{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T19:24:05Z","timestamp":1792610645516,"version":"4.5.0"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:00:00Z","timestamp":1761004800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell. Infect. Microbiol."],"abstract":"<jats:p>Carbapenem-resistant <jats:italic>Pseudomonas aeruginosa<\/jats:italic>(CRPA) poses a serious threat in healthcare settings due to its multidrug resistance and high mortality. Although ceftazidime\/avibactam (CZA) demonstrates potent activity against CRPA, resistance has emerged.<\/jats:p><jats:sec><jats:title>Objective<\/jats:title><jats:p>This study investigates the epidemiology and molecular mechanisms of CZA resistance in CRPA isolates from Ningbo, China.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A total of 279 non-duplicate clinical CRPA isolates (2022\u20132024) were classified as CZA-resistant (CZA-R, n = 68) or CZA-susceptible (CZA-S, n = 211). Carbapenemase genes were detected by PCR, clonality via MLST, biofilm formation by crystal violet assay, and efflux pump expression (<jats:italic>mexA, mexC, mexE, mexY<\/jats:italic>) via qRT-PCR. WGS was performed on selected isolates.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The CZA resistance rate was 24.37%. Risk factors included recent trauma, prior antibiotic exposure, central venous catheterization, and drainage tube placement (all <jats:italic>p<\/jats:italic> &amp;lt; 0.05). The CZA-R group showed higher recurrence (13.2% vs. 4.3%, <jats:italic>p<\/jats:italic> = 0.029) and lower clinical improvement (67.6% vs. 77.3%, <jats:italic>p<\/jats:italic> = 0.029). <jats:italic>bla<jats:sub>NDM<\/jats:sub><\/jats:italic> prevalence was higher in CZA-R (7.4% vs. 0.5%, <jats:italic>p<\/jats:italic> = 0.003), and ST1076 was the predominant clone (29.3%), with higher representation in CZA-R (40.0%). Horizontal gene transfer mediated <jats:italic>bla<jats:sub>NDM<\/jats:sub><\/jats:italic> spread. CZA-R isolates exhibited enhanced biofilm formation (<jats:italic>p<\/jats:italic> &amp;lt; 0.001) and mexA upregulation (2.04-fold, <jats:italic>p<\/jats:italic>\u00a0= 0.007).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our findings indicate a high prevalence of CZA resistance among CRPA isolates in Ningbo, driven by multiple mechanisms including <jats:italic>bla<jats:sub>NDM<\/jats:sub><\/jats:italic> carriage, enhanced biofilm formation, and overexpression of efflux pumps. The dissemination of the high-risk clone ST1076 underscores the need for strengthened infection control measures to curb its spread. These findings provide important insights for optimizing infection control and treatment strategies against CRPA infections in this region.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fcimb.2025.1643755","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T05:36:15Z","timestamp":1761024975000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Study on resistance mechanisms and molecular epidemiology of carbapenem-resistant Pseudomonas aeruginosa to ceftazidime\/avibactam in a certain region of China"],"prefix":"10.3389","volume":"15","author":[{"given":"Xiaohan","family":"Qiao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"He","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruobing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.tim.2022.08.007","article-title":"Respiration-induced biofilm formation as a driver for bacterial niche colonization","volume":"31","author":"AJ","year":"2023","journal-title":"Trends Microbiol."},{"key":"B2","doi-asserted-by":"crossref","first-page":"dlad070","DOI":"10.1093\/jacamr\/dlad070","article-title":"Evolving landscape of carbapenem-resistant Pseudomonas aeruginosa at a single centre in the USA","volume":"5","author":"A","year":"2023","journal-title":"JAC-antimicrobial resistance"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2023.1098944","article-title":"Multifactorial resistance mechanisms associated with resistance to ceftazidime-avibactam in clinical Pseudomonas aeruginosa isolates from Switzerland","volume":"13","author":"B","year":"2023","journal-title":"Front. Cell. infection Microbiol."},{"key":"B4","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s12941-025-00800-z","article-title":"Diverse modes of ceftazidime\/avibactam resistance acquisition in carbapenem-resistant Klebsiella pneumoniae and Pseudomonas aeruginosa from a Chinese intensive care unit","volume":"24","author":"J","year":"2025","journal-title":"Ann. Clin. Microbiol. antimicrobials"},{"key":"B5","article-title":"Microbial evolution through horizontal gene transfer by mobile genetic elements","volume":"17","author":"M","year":"2024","journal-title":"Microbial Biotechnol."},{"key":"B6","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.cmi.2024.11.007","article-title":"Impact of Pseudomonas aeruginosa carriage on intensive care unit-acquired pneumonia: a European multicentre prospective cohort study","volume":"31","author":"C","year":"2025","journal-title":"Clin. Microbiol. infection: Off. Publ. Eur. Soc. Clin. Microbiol. Infect. Dis."},{"key":"B7","doi-asserted-by":"publisher","first-page":"107256","DOI":"10.1016\/j.ijantimicag.2024.107256","article-title":"Resistance to aztreonam-avibactam among clinical isolates of Escherichia coli is primarily mediated by altered penicillin-binding protein 3 and impermeability","volume":"64","author":"C","year":"2024","journal-title":"Int. J. antimicrobial Agents"},{"key":"B8","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1186\/s12879-024-09060-2","article-title":"Clinical success of anti-infective combination therapy compare to monotherapy in patients with carbapenem-resistant Pseudomonas aeruginosa infection: a 10-years retrospective study","volume":"24","author":"Chen","year":"2024","journal-title":"BMC Infect. Dis."},{"key":"B9","article-title":"Clinical efficacy of ceftazidime\/avibactam combination therapy for severe hospital-acquired pulmonary infections caused by carbapenem-resistant and difficult-to-treat Pseudomonas aeruginosa, International Journal of Antimicrobial Agents","author":"Chuanfu","year":"2024"},{"key":"B10","volume-title":"Performance standards for antimicrobial disk susceptibility tests","year":"2024"},{"key":"B11","volume-title":"M02 disk diffusion reading guide","year":"2024"},{"key":"B12","volume-title":"Performance standards for antimicrobial susceptibility testing","year":"2025"},{"key":"B13","doi-asserted-by":"publisher","first-page":"2533","DOI":"10.1007\/s10096-021-04308-0","article-title":"Global Surveillance Program: Ceftolozane\/tazobactam and Ceftazidime\/avibactam in vitro Activity against a Global Collection of Carbapenem-resistant Pseudomonas aeruginosa","volume":"40","author":"CM","year":"2021","journal-title":"Eur. J. Clin. Microbiol. Infect. diseases: Off. Publ. Eur. Soc. Clin. Microbiol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"5644","DOI":"10.1128\/JCM.42.12.5644-5649.2004","article-title":"Development of a multilocus sequence typing scheme for the opportunistic pathogen Pseudomonas aeruginosa","volume":"42","author":"Curran","year":"2004","journal-title":"J. Clin. Microbiol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1093\/jac\/dkp498","article-title":"Development of a set of multiplex PCR assays for the detection of genes encoding important beta-lactamases in Enterobacteriaceae","volume":"65","author":"Dallenne","year":"2010","journal-title":"J. Antimicrob. Chemother."},{"key":"B16","article-title":"Compassionate use of a novel \u03b2-lactam enhancer-based investigational antibiotic cefepime\/zidebactam (WCK 5222) for the treatment of extensively-drug-resistant NDM-expressing Pseudomonas aeruginosa infection in an intra-abdominal infection-induced sepsis patient: a case report, Annals of Clinical Microbiology and Antimicrobials","author":"Dilip","year":"2023"},{"key":"B17","article-title":"Resistance to ceftazidime\u2013avibactam and other new \u03b2-lactams in Pseudomonas aeruginosa clinical isolates: a multi-center surveillance study, Microbiology Spectrum","author":"Felice","year":"2024"},{"key":"B18","article-title":"Review of ceftazidime-avibactam for the treatment of infections caused by pseudomonas aeruginosa","author":"George","year":"2021","journal-title":"antibiotics (Basel Switzerland)"},{"key":"B19","doi-asserted-by":"publisher","first-page":"16463","DOI":"10.1038\/s41598-018-34694-z","article-title":"Interplay between MexAB-OprM and MexEF-OprN in clinical isolates of Pseudomonas aeruginosa","volume":"8","author":"Horna","year":"2018","journal-title":"Sci. Rep."},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1099\/jmm.0.001656","article-title":"Antimicrobial susceptibility study and molecular epidemiology of ceftazidime\/avibactam against Pseudomonas aeruginosa collected from clinical patients in PR China, (2004-2021)","volume":"72","author":"Hu","year":"2023","journal-title":"J. Med. Microbiol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.mib.2021.09.010","article-title":"Pseudomonas aeruginosa: an antibiotic resilient pathogen with environmental origin","volume":"64","author":"Laborda","year":"2021","journal-title":"Curr. Opin. Microbiol."},{"key":"B22","article-title":"Effectiveness of ceftazidime-avibactam for the treatment of infections due to Pseudomonas aeruginosa","author":"Laura","year":"2022","journal-title":"Int. J. Antimicrobial Agents"},{"key":"B23","article-title":"Levofloxacin-induced MexS mutation triggers imipenem-relebactam resistance in a KPC-producing Pseudomonas aeruginosa, International Journal of Antimicrobial Agents","author":"Leilei","year":"2024"},{"key":"B24","doi-asserted-by":"crossref","first-page":"100973","DOI":"10.1016\/j.drup.2023.100973","article-title":"Overexpression of bla(GES-1) due to a strong promoter in the class 1 integron contributes to decreased ceftazidime-avibactam susceptibility in carbapenem-resistant Pseudomonas aeruginosa ST235","volume":"69","author":"Li","year":"2023","journal-title":"Drug Resist. Update"},{"key":"B25","doi-asserted-by":"publisher","first-page":"2324068","DOI":"10.1080\/22221751.2024.2324068","article-title":"Genomic epidemiology and ceftazidime-avibactam high-level resistance mechanisms of Pseudomonas aeruginosa in China from 2010 to 2022","volume":"13","author":"Li","year":"2024","journal-title":"Emerg. Microbes Infect."},{"key":"B26","doi-asserted-by":"publisher","first-page":"38","DOI":"10.37201\/req\/s01.11.2021","article-title":"Ceftazidime-avibactam","author":"Matesanz","year":"2021","journal-title":"Rev. Esp Quimioter"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1186\/s12879-024-10359-3","article-title":"Antimicrobial resistance profile, biofilm forming capacity and associated factors of multidrug resistance in Pseudomonas aeruginosa among patients admitted at Tikur Anbessa Specialized Hospital and Yekatit 12 Hospital Medical College in Addis Ababa, Ethiopia","volume":"24","author":"MD","year":"2024","journal-title":"BMC Infect. Dis."},{"key":"B28","doi-asserted-by":"publisher","first-page":"928","DOI":"10.3389\/fmicb.2020.00928","article-title":"Beyond risk: bacterial biofilms and their regulating approaches, F","volume":"11","author":"Muhammad","year":"2020","journal-title":"ront Microbiol."},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2022.1048633","article-title":"Last resort beta-lactam antibiotics for treatment of New-Delhi Metallo-Beta-Lactamase producing Enterobacterales and other Difficult-to-Treat Resistance in Gram-negative bacteria: A real-life study","volume":"12","author":"R","year":"2022","journal-title":"Front. Cell. infection Microbiol."},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(25)00118-5","article-title":"The WHO Bacterial Priority Pathogens List 2024: a prioritisation study to guide research, development, and public health strategies against antimicrobial resistance, Lancet Infect Dis","author":"Sati","year":"2025"},{"key":"B31","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s13756-019-0533-3","article-title":"Antibiotics versus biofilm: an emerging battleground in microbial communities","volume":"8","author":"Sharma","year":"2019","journal-title":"Antimicrob. Resist. Infect. Control"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.3390\/microorganisms11061614","article-title":"Microbial biofilm: A review on formation, infection, antibiotic resistance, control measures, and innovative treatment","volume":"11","author":"Sharma","year":"2023","journal-title":"Microorganisms"},{"key":"B33","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s00203-025-04251-0","article-title":"Standardizing biofilm quantification: harmonizing crystal violet absorbance measurements through extinction coefficient ratio adjustment","volume":"207","author":"T","year":"2025","journal-title":"Arch. Microbiol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1002\/phar.2209","article-title":"International consensus guidelines for the optimal use of the polymyxins: endorsed by the american college of clinical pharmacy (ACCP)","volume":"39","author":"Tsuji","year":"2019","journal-title":"Eur. Soc. Clin. Microbiol. Infect. Dis. (ESCMID) Infect. Dis. Soc. America (IDSA) Int. Soc. Anti-infective Pharmacol. (ISAP) Soc. Crit. Care Med. (SCCM) Soc. Infect. Dis. Pharmacists (SIDP) Pharmacotherapy"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1111\/1751-7915.14487","article-title":"Antibiotic influx and efflux in Pseudomonas aeruginosa: Regulation and therapeutic implications","volume":"17","author":"Wu","year":"2024","journal-title":"Microb. Biotechnol."},{"key":"B36","article-title":"Antimicrobial susceptibility study and molecular epidemiology of ceftazidime\/avibactam against Pseudomonas aeruginosa collected from clinical patients in PR China, (2004-2021)","author":"Yanyan","year":"2023","journal-title":"J. Med. Microbiol"},{"key":"B37","article-title":"Emergence of a KPC-90 variant that confers resistance to ceftazidime-avibactam in an ST463 carbapenem-resistant pseudomonas aeruginosa strain","author":"Yuexing","year":"2022","journal-title":"Microbiol. Spectr"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2024.1379625","article-title":"The biological function of the type II toxin-antitoxin system ccdAB in recurrent urinary tract infections","volume":"15","author":"Zhang","year":"2024","journal-title":"Front. Microbiol."}],"container-title":["Frontiers in Cellular and Infection Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2025.1643755\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T05:36:18Z","timestamp":1761024978000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2025.1643755\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,21]]},"references-count":38,"alternative-id":["10.3389\/fcimb.2025.1643755"],"URL":"https:\/\/doi.org\/10.3389\/fcimb.2025.1643755","relation":{},"ISSN":["2235-2988"],"issn-type":[{"value":"2235-2988","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,21]]},"article-number":"1643755"}}